
Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article
Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic
read more
Can Ozempic Affect Your Eyes or Vision?
Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a
read more
Texas Retina Associates Participating in Phase III Clinical Trial for Choroidal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina is participating in the Phase III AU-011 clinical trial (CoMpass) for treatment of small choroidal (ocular) melanoma. Together with Aura Biosciences,
read more
Dr. Wang Presented Study Results of New Wet AMD Treatment Approach at the ARVO 2025 Meeting
On May 9, 2025, Texas Retina’s Robert C. Wang, MD, presented “Top Line Results from ODYSSEY: A Phase IIb Study of Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-related Macular Degeneration” at
read more
Dr. Nikisha Kothari Leads Eyetube Interview on a Challenging Surgical Case
Texas Retina’s Nikisha Kothari, MD, recently interviewed one of the 2025 Vit-Buckle Society Meeting presenters about a challenging case for Eyetube. She talked with Andrew Tsai, MD, an adult and pediatric retinal
read more
Dr. Rene Choi Selected as “One to Watch” in Retina Today
Texas Retina’s Dr. Rene Y. Choi has been selected as a “One to Watch” in the April 2025 issue of Retina Today. This feature highlights individuals identified as future leaders in the
read more